SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC:…
LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…
Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase…
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing…
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected…
ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced…
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine…
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”)…